Approximately 21 subjects with amyotrophic lateral sclerosis (ALS) will be randomized (6 to 1) to receive by mouth seven morning doses of CC100 or placebo for 7 days. Subjects are required to stay in the Clinic for approximately 9 hours following the first and last dose. Subjects will also have a mid-week clinic visit and will be contacted by phone within 3 to 5 days after the last dose.
Funding Source - FDA OOPD

Start Date07 Apr 2017

Sponsor / Collaborator

Chemigen, Inc.

NCT02050334 / CompletedPhase 1

Protocol CC100A CC100: Safety and Tolerability of Single Doses

The purpose of this study is to see if CC100, given by mouth, is safe and is tolerated in increasing doses. How long the drug remains in the body will also be calculated.

Start Date01 Nov 2013

Sponsor / Collaborator

Chemigen, Inc.

NCT02744703 / CompletedNot ApplicableIIT

Professor, Ege University Faculty of Dentistry

Matrix metalloproteinases (MMPs); activated by the application of adhesive systems on dentin cause degradation of the collagen proteins and loss of bond strength in adhesive restorations. Caffeic acid phenethyl ester (CAPE) showed inhibitory activities on dentinal MMPs. It is hypothesised that dentin pretreatment with CAPE, as an MMP inhibitor, would be beneficial for the bonding of resin material and tooth substrate over the course of time. This study evaluated the effect of 5 % CAPE pretreatment on the microtensile bond strength of a nanohybrid resin restoration applied with total-etch or self-etch adhesive systems on 10 patients (12-18 yrs). Two standard cavities (3 x 3 x 4 mm) prepared on the occlusal surfaces of one of the two premolar teeth in each patient were randomly assigned into four treatment groups (n=10); 5% CAPE pretreatment and total-etch adhesive (TC), Total-etch adhesive (control) (T), 5% CAPE pretreatment and self-etch adhesive (SC), Self-etch adhesive (control) (S) followed by restoration and 3 months of intra-oral functioning. After teeth extraction, the specimens were stored in distilled water+thymol solution at 4°C to inhibit microbial growth and used in one week period. Dentin-composite sticks were obtained from each restoration for µTBS tests and scanning electron microscopy (SEM) evaluation. Failure mode analysis was performed microscopically. Data were analysed statistically using Repeated Measure ANOVA (p < 0.05). Dentin pretreatment with CAPE solution (5%) for 60 seconds significantly increased the composite resin restorations' bond strengths to dentin applied with either total-etch or self-etch adhesive system. Thus it can be used as an MMP inhibitor prior to the the resin restorations. However further long term clinical studies are needed to support the use of CAPE pretreatment along with self-etch and total-etch adhesive systems.

Start Date01 Apr 2013

Sponsor / Collaborator

Ege Universitesi

100 Clinical Results associated with Caffeic acid phenethyl ester

100 Translational Medicine associated with Caffeic acid phenethyl ester

100 Patents (Medical) associated with Caffeic acid phenethyl ester

1,059

Literatures (Medical) associated with Caffeic acid phenethyl ester

31 Dec 2024·Renal Failure

Caffeic acid phenethyl ester restores mitochondrial homeostasis against peritoneal fibrosis induced by peritoneal dialysis through the AMPK/SIRT1 pathway

Article

Author: Zeng, Ying ; Zhang, Wenwen ; Lu, Ying ; Gao, Luyan ; Hu, Ji ; Song, Kai

Increasing evidence suggests that peritoneal fibrosis induced by peritoneal dialysis (PD) is linked to oxidative stress. However, there are currently no effective interventions for peritoneal fibrosis. In the present study, we explored whether adding caffeic acid phenethyl ester (CAPE) to peritoneal dialysis fluid (PDF) improved peritoneal fibrosis caused by PD and explored the molecular mechanism. We established a peritoneal fibrosis model in Sprague-Dawley rats through intraperitoneal injection of PDF and lipopolysaccharide (LPS). Rats in the PD group showed increased peritoneal thickness, submesothelial collagen deposition, and the expression of TGFβ1 and α-SMA. Adding CAPE to PDF significantly inhibited PD-induced submesothelial thickening, reduced TGFβ1 and α-SMA expression, alleviated peritoneal fibrosis, and improved the peritoneal ultrafiltration function. In vitro, peritoneal mesothelial cells (PMCs) treated with PDF showed inhibition of the AMPK/SIRT1 pathway, mitochondrial membrane potential depolarization, overproduction of mitochondrial reactive oxygen species (ROS), decreased ATP synthesis, and induction of mesothelial-mesenchymal transition (MMT). CAPE activated the AMPK/SIRT1 pathway, thereby inhibiting mitochondrial membrane potential depolarization, reducing mitochondrial ROS generation, and maintaining ATP synthesis. However, the beneficial effects of CAPE were counteracted by an AMPK inhibitor and siSIRT1. Our results suggest that CAPE maintains mitochondrial homeostasis by upregulating the AMPK/SIRT1 pathway, which alleviates oxidative stress and MMT, thereby mitigating the damage to the peritoneal structure and function caused by PD. These findings suggest that adding CAPE to PDF may prevent and treat peritoneal fibrosis.

01 Dec 2024·Molecular Biology Reports

Interaction of olive oil-based propolis and caffeic acid phenethyl ester with methylprednisolone used in the treatment of human acute myeloid leukemia

Article

Author: Ozcimen, A Ata ; Silici, Sibel ; Dogan, Hamide

BACKGROUNDMethylprednisolone (MP) is a pharmaceutical agent employed in the management of Leukemia, which is a systemic malignancy that arises from abnormalities in the hematological system. Numerous investigations in the field of cancer research have directed their attention towards propolis, a natural substance with significant potential as a treatment-supportive agent. Its utilization aims to mitigate the potential adverse effects associated with chemotherapy medications. The objective of this study was to examine the impact of olive oil-based propolis (OEP) and caffeic acid phenethyl ester (CAPE) on the treatment of acute myeloid leukemia, as well as to determine if they exhibit a synergistic effect when combined with the therapeutic support product methylprednisolone.METHODS AND RESULTSThe proliferation of HL-60 cells was quantified using the WST-8 kit. The PI Staining technique was employed to do cell cycle analysis of DNA in cells subjected to OEP, CAPE, and MP, with subsequent measurement by flow cytometry. The apoptotic status of cells was determined by analyzing them using flow cytometry after staining with the Annexin V-APC kit. The quantification of apoptotic gene expression levels was conducted in HL-60 cells. In HL-60 cells, the IC₅₀ dosages of CAPE and MP were determined to be 1 × 10^- 6 M and 5 × 10^- 4 M, respectively. The HL-60 cells were subjected to apoptosis and halted in the G₀/G₁ and G₂/M phases of the cell cycle after being treated with MP, CAPE, and OEP.CONCLUSIONSPropolis and its constituents have the potential to serve as effective adjunctive therapies in chemotherapy.

01 Dec 2024·Current Medicinal Chemistry

Caffeic Acid Phenethyl Ester: A Potential Therapeutic Cancer Agent?

Review

Author: Chirumbolo, Salvatore ; Lenchyk, Larysa ; Peana, Massimiliano ; Lysiuk, Roman ; Hudz, Nataliia ; Storchylo, Olha ; Koshovyi, Oleh ; Hangan, Tony ; Bjørklund, Geir ; Antonyak, Halyna

Background:Propolis and its major phenolic compound, caffeic acid phenethyl ester (CAPE), have garnered considerable scientific interest due to their anti- inflammatory properties and potential therapeutic applications.Objectives:This narrative review explores the potential utility of CAPE in cancer treatment.Methods:We comprehensively reviewed relevant studies from scientific databases (PubMed and Web of Science) from 2000 to 2022. Our search focused on keywords such as cancer, natural drugs, caffeic acid phenethyl ester, CAPE, cancer cell lines, antitumor effects, and propolis.Results:CAPE exhibits diverse biological benefits, including antimicrobial, antioxidant, antiviral, anti-inflammatory, cytotoxic, and potentially anti-carcinogenic properties. Numerous studies have demonstrated its wide-ranging antitumor effects on various cancer cell lines, including growth inhibition, apoptosis induction, tumor invasiveness prevention, malignancy suppression, and anti-angiogenic activity.Conclusion:Following comprehensive preclinical toxicity assessments, further evaluation of CAPE's efficacy and safety through clinical trials is highly recommended to elucidate its potential health benefits in diverse forms of human cancer.

News (Medical) associated with Caffeic acid phenethyl ester

27 Feb 2023

·www.prnewswire.com

Cymbiotika Announces Launch of New Supplement, ParaX ™

This all-natural formula supports overall whole-body wellness SAN DIEGO, Feb. 27, 2023 /PRNewswire/ -- Cymbiotika, the leading supplement brand known for creating clean, science-backed supplements, announced its newest product, ParaX™. ParaX is a comprehensive approach to balancing the gut microbiome, enhancing detox pathways, fortifying the immune system, and providing whole-body wellness. ParaX utilizes vitamins, minerals, standardized herbal extracts, fatty acids, and phenols encapsulated within powerful ozonated, oxygen-infused oils. What makes ParaX unique is that it was designed inside a gel capsule with suspended ParaX-Spheres. The formula also contains a powerful blend of ozonated oils made of monolaurin, coconut, thyme, clove, olive, and oregano. This combination provides a wide range of antimicrobial and antiseptic agents. The formula also contains CAPE (Caffeic Acid Phenethyl Ester), a highly bioactive compound found in bee propolis and utilized for its extraordinary antioxidant and immune properties, and Andrographolide, which is shown to support the immune system, promote a healthy inflammatory response and support the body during bacterial and viral infections. "We designed this formula to offer a proactive approach to combating the overgrowth of bacteria, microbes, and other foreign invaders in our microbiome that can cause many diverse health issues. ParaX is a daily supplement intentionally formulated for overall wellness and immune support rather than act as a harsh, one-time cleanse," said Dr. Pejman Taghavi, a Cymbiotika's Board of Advisors member. Cymbiotika's ParaX is a powerful supplement that provides an extra line of defense against bacteria, microbes, and foreign invaders that the body is exposed to. ParaX retails for $92 and is available for purchase through the Cymbiotika website. Customers over the age of 18 should take three capsules daily, with water or juice, as directed by a qualified healthcare practitioner. The formula was designed for individuals to take three weeks on and one week off. ParaX can be taken any time of the day, but it is crucial to be consistent with the time it is taken. For increased effectiveness, take alongside Cymbiotika's Liposomal Vitamin C. About Cymbiotika Cymbiotika is an innovative wellness brand based in San Diego. With the motto, "Your mind and body deserve the best," Cymbiotika is driven by the higher purpose of inspiring everyday people to achieve their optimal health. Founded in 2018, Cymbiotika uses the most advanced bioavailable absorption technology and sources only the highest quality plant-based nutrients to resolve specific nutritional deficiencies and support healthy aging, detoxification, and longevity. Cymbiotika never uses synthetics, GMOs, fillers, chemicals, preservatives, or additives in its products. For more information, visit . SOURCE Cymbiotika

Microbial therapy

100 Deals associated with Caffeic acid phenethyl ester

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Amyotrophic Lateral Sclerosis	Phase 3	US	Chemigen, Inc.	27 Oct 2013
Squamous cell carcinoma of the oral cavity	Preclinical	TW	Mackay Medical College	01 Sep 2017
Colorectal Cancer	Preclinical	US	The National Institute of Environmental Health Sciences	01 May 2007
Colorectal Cancer	Preclinical	KR	Andong National University	01 May 2007
Colorectal Cancer	Preclinical	US	University of Tennessee	01 May 2007

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02050334 (CC100A, CTgov)	Phase 1	-	18	CC100 (CC100 (3 Single Doses))	nofweyahqh(yqorwtiagu) = alaxdnopcb kpogdvabks (povwpddpzt, lxupnydumb - yefyjrfvvm) View more	-	29 Apr 2015
				Placebo+CC100 (CC100 (2 Single Doses) & Placebo(1 Dose))	nofweyahqh(yqorwtiagu) = milukpdszb kpogdvabks (povwpddpzt, vskocmvpvt - xrmkmmlccf) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Caffeic acid phenethyl ester

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation